Tyrosinase is an enzyme unique to pigment-forming cells. Methods using this transcript for detection of melanoma cells in blood have given divergent results. Quantitative analytical procedures are therefore needed to study the analytical performance of the methods. Methods: Mononucleated cells were isolated by Percoll centrifugation. RNA was isolated by each of three methods: Ultraspec TM -II RNA isolation system, FastRNA
The number of melanoma cells in blood from patients with malignant melanoma is largely unknown. However, the expression of mRNA of selected genes from a specific tumor cell can be detected by the use of reverse transcriptase for the synthesis of cDNA followed by amplification of the cDNA by use of PCR. This principle was used by Smith et al. (1 ) to identify tyrosinase mRNA as a method to detect melanoma cells in blood. The specificity of the method depends on the facts that melanocytes expressing tyrosinase are tissue bound and do not migrate into blood and that tyrosinase is not expressed in other cells. In theory, one specific cell can be detected in the sample (usually 2-4 mL of blood) with this technique.
Since 1991, several investigations (2) (3) (4) (5) have shown that melanoma cells are present in the circulation of patients with disseminated cutaneous malignant melanoma, and that the presence of melanoma cells (read transcripts from melanoma cells) seems to be positively correlated to rapid progress of the disease (2, 4 ) . At the time of diagnosis, 10 -14% of patients with primary malignant melanoma were found to have detectable numbers of melanoma cells in blood with this technique (1, 4, 5 ) . In cases with dissemination of cutaneous melanoma, 50 -100% of the patients had melanoma cells in blood (1, 2, 4, 5 ) . It was shown that patients with uveal melanomas had no detectable melanoma cells in their blood (3 ) .
Several reports continue to be published on various aspects on the suitability of melanoma cells identification in blood for evaluation of tumor progression. Thus, Reinhold et al. (6 ) concluded that the analysis of blood samples by reverse transcription-PCR (RT-PCR) 3 for tyrosinase mRNA is not suitable for the early detection of tumor progression in melanoma patients. A similar opinion was expressed by Gläser et al. (7 ) . Farthmann et al. (8 ) , on the other hand, concluded that RT-PCR positivity in early melanoma stages may indicate increased risk for the development of hematogenous metastases and may be of value as a progression marker. Farthmann et al. (8 ) performed nested primer analysis on duplicates of each of two separated RNA preparations and obtained a definitive result in 98.4% of 123 melanoma patients examined. Their attempts to define the final results as either positive or negative illustrate the need for quantitative analysis of tumor-specific mRNA.
For semiquantitative analysis of the number of melanoma cells in peripheral blood, Brossart et al. (9 ) described a method combining RT-PCR and Southern blotting, and found that the amount of circulating cells correlated with the tumor burden. Attempts were also made by Curry et al. (10 ) to change their assay into a quantitative method by the use of an internal standard (IS). Calibration was made by comparing the quotient between the sample and IS signals with that from a selected melanoma cell line, thus indicating a specific number of cells in the patients' blood. These "quantitative" methods, therefore, can be used when monitoring changes in the number of melanoma cells in blood.
We here present a method using internal standardization technique, according to the principles described by Lehtovaara et al. (11 ) for quantification of tyrosinase mRNA in blood. The suitability of the method is illustrated by comparison of the results with analysis of 5-S-cysteinyldopa in plasma and urine of a patient. The potential for further improvements of PCR methods-and perhaps the reason for the divergent results in clinical investigations-is illustrated by the finding of great variability in results when different procedures were used to extract RNA from blood samples.
Materials and Methods materials
We used two of the primers described by Smith et al. (1 ) in their nested PCR, e.g., HTYR3 and HTYR4 (for amplification). These two primers are located in exons 2 and 3, respectively, of the tyrosinase gene, and on amplification of tyrosinase, their use gives a 207-bp fragment. The primers were synthesized and HPLC purified by CyberGene AB (Stockholm, Sweden).
To detect the tyrosinase and IS PCR products we used 2,4-dinitrophenol (DNP)-labeled probes. The tyrosinasespecific probe (5ЈDNP-GGGGAGCCTTGGGGTTCTGG-3Ј) and the IS-specific probe (5ЈDNP-CGGAGCCCC-GAAACCACATC-3Ј) were synthesized by Scandinavian Gene Synthesis (Kö ping, Sweden).
cell culture
For in vitro studies, the cell lines SK-Mel 28 (ATCC) and JKM86-4 (12 ) were used. SK-Mel 28 was cultured in minimal essential medium with Hank's salts containing 100 mL/L fetal bovine serum (ICN Biomedicals), 2 mmol/L l-glutamine, nonessential amino acids, 1 mmol/L sodium pyruvate, 10 000 units/L penicillin, and 10 mg/L streptomycin. JKM86-4 was grown in two parts of minimal essential medium with Earl's salts and 1 part of Leibovitz's L-15 medium containing 150 mL/L fetal bovine serum (ICN Biomedicals), 2 mmol/L l-glutamine, 4.7 mg/L insulin (Sigma), nonessential amino acids, 100 mg/L gentamicin, 10 000 units/L penicillin, and 10 mg/L streptomycin. All reagents were from Life Technologies. The cells were grown in humidified air with 5% CO 2 .
construction of tyrosinase mRNA calibrator and internal standard
The tyrosinase cDNA calibrator (TS) was a 207-bp fragment generated by amplifying cDNA from SK-Mel 28 cells using the HTYR3 and HTYR4 primers. The tyrosinase PCR product was subcloned in an AT vector (Invitrogen), and the sequence was confirmed by automated fluorescence sequencing. The TS fragment was purified using a QIAquick PCR Purification Kit (Qiagen) and quantified by absorbance at 260 nm. The TS was diluted to 1 000 000, 10 000, 1000, 100, and 10 molecules/25 L and stored in aliquots at 2-8°C. Amplification of the TS samples in the presence of IS (see below) was used to generate the calibration curve.
The IS was a 207-bp fragment constructed by a technique of oligonucleotide overlap extension and PCR amplification. The IS PCR amplification product was subcloned in an AT vector, and the sequence was confirmed by automated fluorescence sequencing. The IS fragment was purified using a QIAquick PCR Purification Kit and quantified by absorbance at 260 nm. The IS was included in the PCR reaction mixture at a defined concentration, 250 copies/reaction. To achieve similar amplification efficiency between the IS and the tyrosinase target, the IS was designed to have a base sequence identical to that of the tyrosinase target except for a 20-bp probe-binding region.
patients and healthy controls
Unselected patient material was used to evaluate the precision of the method. Blood samples from 65 patients, treated earlier for malignant melanoma, were included in the study. Repeated samples were taken from several patients, and a total of 226 samples were analyzed. Healthy blood donors were used as negative controls. We also performed case studies in five cases; one of them is reported to show the possible use of the method. This patient underwent an axillary lymph node dissection because of regional metastatic disease. Pulmonary x-ray and ultrasound of the liver showed no metastases. Because the patient was at high risk of developing systemic metastases, he started adjuvant treatment with interferon␣2b (Introna ® ; Schering-Plough).
blood collection and cell separation
Blood was collected in 5-mL Vacutainer Tubes (Becton Dickinson) containing 0.5 mL of 0.13 mol/L sodium citrate. After mixing, 4-mL aliquots of blood were mixed with 4 mL of phosphate-buffered saline containing 0.13 mol/L citrate (PBS-citrate) in a 15-mL Falcon tube, and 4 mL of 67% Percoll (Pharmacia Biotech) in PBS was layered under the blood with a syringe. The tube was centrifuged at 1000g for 30 min at 20°C without braking. The mononuclear cell layer between the plasma and the Percoll solution was collected and washed once with 11 mL of PBS-citrate by centrifugation at 800g for 10 min at 20°C. The pellet was suspended in 0.25 mL of PBS-citrate.
RNA extraction
RNA was extracted using the Ultraspec TM -II RNA isolation system (Biotecx). The samples were homogenized for three 30-s time periods using an Ultra Turrax (Tamro Lab) in the Ultraspec II mixture. Chloroform was then added, and the sample was centrifuged. The upper phase was collected, and isopropanol and RNATac TM Resin were added. After centrifugation, the pellet was washed twice with 750 mL/L ethanol, and then the pellet was dried in a Savant vacuum extractor (Tectum). Finally, the sample was resuspended in 120 L of RNase-free water.
For comparison, RNA was also extracted with the FastRNA TM GREEN Kit (Bio 101) according to the protocol from the manufacturer. Briefly, the sample was added to a FastPrep TM GREEN tube together with CRSR-GREEN, PAR, and CIA solutions. The tube was vortexmixed twice for 1 min each, with cooling on ice between. After centrifugation, the upper phase was collected. CIA solution was added, and after another centrifugation, the upper phase was collected again. The RNA was allowed to precipitate in DIPS. After centrifugation, the pellet was washed twice with SEWS solution. Finally, the RNA was suspended in 120 L of SAFE solution.
Alternatively, RNA was extracted from 1.5 mL of blood using the QIAamp RNA Blood Mini Kit (Qiagen) according to the manufacturer's instructions. Briefly, the erythrocytes were lysed with EL buffer, and the remaining cells were pelleted by centrifugation. The leukocytes were then lysed with RLT buffer and homogenized with the QIAshredder. After addition of one volume of 700 mL/L ethanol, the homogenate was applied to a QIAamp RNA mini spin column. The column was washed once with RW1 buffer and twice with RPE buffer. Finally, the RNA was eluted with 2 ϫ 60 L of RNase-free water. We also extracted RNA from Percoll-separated cells. In this case, 4 mL of blood was used and the mononuclear cell pellet was lysed directly with the RLT buffer.
first-strand cDNA synthesis RNA (30 L) was denatured at 70°C for 5 min and then placed on ice. To the RNA, 30 L of cDNA mixture was added. The final concentrations were as follows: 1ϫ First Strand Buffer (Life Technologies), 7.5 mmol/L dithiothreitol (Life Technologies), 500 mol/L dNTPs (Pharmacia Biotech), 50 mol/L random hexamer (Pharmacia Biotech), 1 ϫ 10 6 units/L RNasin (Promega), and 10 ϫ 10 6 U/L murine Moloney leukemia virus reverse transcriptase (Life Technologies). A drop of mineral oil was added to avoid condensation. First-strand cDNA synthesis was performed at 40°C for 45 min, and the reaction was then heated for 5 min at 95°C.
PCR
Twenty-five microliters of first-strand cDNA or tyrosinase calibrator (TS) was amplified in a total volume of 100 L containing (final concentrations) 50 mmol/L Tris (pH 8.
.5 ϫ 10 6 IS molecules/L, and 25 000 U/L AmpliTaq (PE Applied Biosystems). The PCR was performed in a Perkin-Elmer TC 9600 thermal cycler for 35 cycles, and the PCR profile used was as follows: 94°C for 2 min as an initial denaturation step, followed by 35 cycles of 30 s at 94°C, 20 s at 60°C, and 30 s at 72°C. A final elongation for 10 min at 72°C ended the profile, and the amplification products were kept at 4°C.
colorimetric detection
Binding buffer (100 L; AB Sangtec Medical) was added to each PCR tube, and 50-L aliquots were transferred to two wells of a streptavidin-coated microtiter plate (Labsystems Oy), one well for measurement of the TS amplicon and one well for measurement of the IS amplicon. The plate was placed in a shaker, and the biotinlabeled strand was allowed to bind to the streptavidin. After 15 min, the complementary strand was released by the addition of 50 L of a solution containing 100 mmol/L NaOH and 300 mmol/L NaCl. The plate was shaken for 1 min and washed six times with wash buffer (25 mmol/L Tris-HCl, pH 7.5, 1.25 mmol/L NaCl, 2 mmol/L MgCl 2 and 3 mL/L Tween).
DNP-labeled probes (50 L), one TS specific and one IS specific, were added to the respective samples. The probes were allowed to hybridize for 15 min at 55°C.
After the wells were washed six times, 50 L of anti-DNP antibody conjugated to alkaline phosphatase (AB Sangtec Medical) was added and incubated for 15 min at room temperature. The plate was washed six times, and 100 L of substrate (4 g/L pNPP in substrate buffer; AB Sangtec Medical) was added. The absorbance at 405 nm was measured after 4, 10, and 30 min.
calculations for quantitative analysis A blank, to which only substrate buffer was added, was included in each experiment. The absorbance of the blank at 405 nm (A 405 ) was subtracted from the other values. The subtracted values was used to calculate a ratio between the TS DNA and the IS DNA for each sample.
A calibration curve was generated by plotting the mean ratio (n ϭ 3) vs the TS concentration in a log-log scale, and an equation of the calibration curve was calculated using linear regression. This equation was used to calculate the tyrosinase transcript concentration of the blood samples.
analysis of 5-S-cysteinyldopa 5-S-Cysteinyldopa is produced in pigmented tissue and increases in dissemination of malignant melanoma (13 ) . Therefore, 5-S-cysteinyldopa was measured in serum (14 ) and urine (15 ) for comparison in a patient with a high risk of developing melanoma metastases.
statistical method
The results of different RNA extraction kits were evaluated by ANOVA.
Results

calibration curves
Examples of the A 405 profiles of TS and IS and the corresponding calibration curves are shown in Fig. 1 . Two hundred fifty copies of the IS were included in each reaction. As can be seen in Fig. 1A , the IS acts as an internal standard when the TS is Ͻ10 3 copies/sample and as a competitor at higher concentrations of TS. Table 1 shows the results for the calibration curves from 28 analyses obtained over a period of 6 months. During this period, the same batch of reagents for PCR and colorimetric detection was used. Within this period, the imprecision was Ͼ70% when Յ100 transcripts per reaction were analyzed. For higher number of transcripts, the long-term imprecision was Ͻ50%.
The ratio between the A 405 values of TS and IS showed no tendency to change, and the absorbance values were also stable over time, indicating that the reagents were stable for at least 6 months (Fig. 2) .
validation of the method
For analysis of total variation during a 6-month period, RNA from 10 6 melanoma cells (SK-Mel 28) was prepared and diluted 50 000-, 5000-, and 500-fold. The diluted RNA was aliquoted and frozen. Subsequently, the different dilutions were included as controls in the PCR. After cDNA synthesis, the sample was split into duplicates and analyzed. For comparison, the results of these controls were also converted to transcripts/mL of blood. Thus, the means (Ϯ SD) of the controls were 24 (Ϯ 24) transcripts/mL of blood (n ϭ 12), 1775 (Ϯ 882) transcripts/mL of blood (n ϭ 16), and 17 929 (Ϯ 8601) transcripts/mL of blood (n ϭ 14), respectively, and the corresponding CVs were 102%, 50%, and 48%. When calculated from the duplicates in the PCR analyses, the same mean values were obtained and the CVs were 80%, 27%, and 27%, respectively. From the SD of 24 transcripts/mL obtained with the controls having the lowest number of transcripts/mL, a detection limit of 48 transcripts/mL of blood was obtained when the detection limit was defined as 2 SD above zero. The three different dilutions corre- Blood samples (n ϭ 18) from blood donors were also investigated. None of them had a value higher than the detection limit of 48 transcripts/mL of blood. A subset of 16 samples was analyzed both by the present method and by the method published by Smith et al. (1 ) . The negative samples (n ϭ 4) had values below the detection limit, and the positive samples had values ranging from 139 to 9140 transcripts/mL (Fig. 3) .
A total of 226 samples from 65 patients were analyzed, and the imprecision was calculated from the results above the detection limit (n ϭ 56). The cDNA sample was split into duplicates for evaluation of intraassay imprecision. The results (Table 2) showed pooled CVs of 49 -57% for samples containing different number of transcripts/mL of blood. Higher intraassay CVs were obtained for the samples (Table 2 ) than for the calibrators (Table 1 ). This might be expected because the samples contain a complex matrix of components from the blood that are not present in the calibrators.
comparison of different rna extraction kits
Melanoma cells were added to blood from six healthy donors to give a concentration of 500 cells/mL. RNA was extracted by three different kits: the Ultraspec-II RNA isolation system, the FastRNA GREEN Kit, and the QIAamp RNA Blood Mini Kit. All of the kits used mononuclear cells prepared from 4 mL of blood for RNA extraction. The RNA was also extracted by the QIAamp RNA Blood Mini Kit from 1.5 mL of whole blood. The experiment was performed with the melanoma cell lines JKM86-4 and SK-Mel 28. Fig. 4 shows that QIAamp RNA was the best method (P Ͻ0.001 for both cell lines), giving at least 15-fold higher values than the Ultraspec-II RNA extraction kit.
case study
The use of the method in monitoring melanoma patients is illustrated by the results shown in Table 3 . A patient receiving adjuvant treatment with interferon-␣2b (Introna; Schering-Plough) was monitored by repeated analysis of 5-S-cysteinyldopa in the patient's blood and urine to- Fig. 2 . Stability of response of calibrators over time.
The calibrators were analyzed in each assay. There was no sign of decrease of the TS/IS ratio over time. Tyrosinase cDNA was diluted to 10 6 (Ⅺ), 10 4 (f), 10 3 (ƒ), 10 2 (), and 10 (E) copies/sample, and aliquots were stored in the refrigerator until analysis. In addition, as a negative control, nonsense DNA (F) was analyzed. gether with analysis of tyrosinase mRNA in his blood. The 5-S-cysteinyldopa values were well within the reference values until the last collected sample. His initial values for tyrosinase mRNA were moderately increased (above the detection limit of 48 transcripts/mL) until the last collected sample, when it increased markedly in a fashion similar to 5-S-cysteinyldopa. Before that there were no clinical signs of metastases. A computerized tomography of the abdomen was then performed, and a spleen metastasis was found.
Discussion
We have developed a quantitative RT-PCR method that utilizes a specific probe and an enzyme-linked assay to detect the amplification products. Previously, Brossart et al. (9 ) reported a semiquantitative method in which the tyrosinase transcript was correlated to a housekeeping gene. Two quantitative methods have also been described (10, 16 ) in which a constructed IS that was coamplified with the same primer pair was used. The IS, however, was a different size from the tyrosinase transcript. The use of ELISA for detection makes it possible to use an IS that has the same size and a similar sequence, and hence a similar efficiency in the PCR, as the tyrosinase transcript except for the bases that hybridize to the probe. For the determination of the imprecision of our method, we used unselected material from 226 samples sent to the laboratory. Of these samples, 25% had tyrosinase expression above the detection limit of 48 transcripts/mL of blood. This corresponds to 1.3 melanoma cells/mL of blood, if compared with the melanoma cell line SK-Mel 28. This cell line often has been used to denote the sensitivity of both qualitative (1, 8, 17 ) and quantitative methods (9, 18 ) . Thus, the sensitivity of our method compares well with other methods as far as detection is concerned.
Great variations in the number of patients with a detectable number of melanoma cells in the blood have been reported (17 ) . This may be attributable to several factors. Methodological differences must be taken into consideration. Most authors have used the primers designed by Smith et al. (1 ) . However, RNA extraction methods differ. The use of whole blood in combination with phenol-chloroform extraction described by Chomczynski and Sacchi (19 ) is popular. Furthermore, extraction can be made from both whole blood and after density centrifugation. In the present report, we studied the extraction procedures by comparing three different commercially available methods. The Ultraspec-II RNA isolation system and the FastRNA GREEN Kit are both variants of the method of Chomczynski and Sacchi (19 ) and showed less recovery than the QIAamp RNA Blood Mini Kit. The QIAamp RNA kit, which uses silica-based membranes to bind RNA, gave a 15-fold higher result than the Ultraspec-II method (P Ͻ0.001). In the comparison between extraction from whole blood and after Percoll, similar separation results were obtained. To avoid the risk of losing cells from patients' blood, we chose to use whole blood. Similar studies are needed to control the effectiveness and the variation in the RNA extraction step. These types of studies are not possible with qualitative methods but need quantitative methods.
The use of housekeeping genes to control for the variation in the RNA extraction and cDNA synthesis is not suitable when a fixed amount of blood is analyzed. Because the number of leukocytes in blood samples from healthy individuals can vary at least threefold, an extra variation is introduced if the result is correlated to a housekeeping gene. We instead used controls composed of cultured melanoma cells to evaluate the differences in the cDNA synthesis and PCR analysis. The two highest controls showed an imprecision of 50%, whereas the lower control had a CV of 102%.
We have obtained rather high overall CVs for the Melanoma cells (500/mL) from the JKM86-4 (f) or SK-Mel 28 (Ⅺ) cell lines were added to blood from donors, and RNA was extracted with different procedures. For Ultraspec (U), FastRNA (F), and a variant of QIAamp RNA (QM), mononuclear cells prepared by Percoll separation from 4 mL blood were used. RNA was also extracted from 1.5 mL of whole blood with QIAamp RNA (QB). The results were corrected for volumes used. ***, P Ͻ0.001 The results of the different kits were compared with QIAamp RNA extraction from whole blood; bars, SD. controls as well as the calibrators compared with other types of analytical methods. However, one has to bear in mind that this method is complex, with several steps where variation can be introduced. In addition, larger variations than in other methods have to be expected because differences that might be small at the beginning will also be amplified in the PCR. This could be one explanation for the high intraassay variation. We also reported here the results from a patient followed for a longer period, using our PCR method together with the tumor marker 5-S-cysteinyldopa. In the first samples taken, the patient had tyrosinase expression above the detection limit, corresponding to 2-3 SK-Mel 28 cells/mL. The number of tyrosinase transcripts increased to 1860 transcripts/mL of blood before any clinical evidence of metastasis was found. This illustrates the usefulness of our method. If compared to the SK-Mel 28 cell line that we used in our in vitro experiments, 1860 transcript would correspond to ϳ50 cells. However, Curry et al. (10 ) showed with a quantitative method that the number of transcripts could vary tremendously in different cell lines.
It should be noted that serum and urine 5-S-cysteinyldopa increased at the same time as the number of transcripts (melanoma cells) in blood. Both of these changes can be considered as expression of increases in tumor burden, and when the results were reported, further clinical investigations revealed the presence of spleen metastases. These results are consistent with the prerequisite of melanotic cells, i.e., the cells must express tyrosinase. One reason why both of these methods might fail would be that the melanoma cells lack tyrosinase.
Further validation studies of methods remain to be done, and by improvement of methods, ambiguities regarding the clinical usefulness of the analysis hopefully will be resolved.
